Spread and Course of COVID-19 Infections

NCT04377724 | Completed

• 1 other identifier: 20-05
• Study Type: observational
• Target: 2,910
• Locations: 1 country
• Sites: 1

Brief Summary

The overall goal is to study the immune response to SARS-CoV-2 infection over the period of one year in the blood of a representative cohort of ETH students/employees.

Conditions

Covid-19; Virus Disease

Outcome Measures

Primary Outcomes (1)

• seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens

  12 months

Secondary Outcomes (3)

• the property of peripheral blood mononuclear cells before and after an infection with SARS-CoV-2 as opposed to other pathogens

  12 months

• the property of IgM and IgA antibody titers against the nucleocapsid protein of SARS-CoV-2 in symptomatic as well as asymptomatic COVID-19 infections over the course of time following an infection

  12 months

• the immune response to common-cold (corona)virus and influenza virus infections in patients with COVID-19 infections

  12 months

Study Arms (1)

ETH cohort

employees or students at ETH Zurich, Switzerland

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

The cohort consists of initially healthy volunteers, all employees or students of ETH. Inclusion into the longitudinal study will be carried out in strict response to the STOP safety concept of the Safety, Security, Health and Environment administrative department of ETH.

You may qualify if:

• ETH employee or ETH student and their family members living in the same household at the start of the study
• Between 18 and 64 years of age at the start of the study
• Signed informed consent

You may not qualify if:

• Age over 64 years at the start of the study
• In quarantine or self-confinement at the start of the study
• Active COVID-19 infection at the start of the study:
• Diagnosed with a laboratory test
• Suspected based on typical symptoms such as fever (\>38°C), acute pulmonary ex-acerbation or sudden loss of gustatory taste
• The following medical condition
• With continuous steroid therapy/ chemotherapy/immunsuppressive therapy
• In treatment for cancer
• With severe autoimmune disease

Sponsors & Collaborators

• Goldhahn Jörg: lead

Study Sites (1)

ETH

Zurich, 8092, Switzerland

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

CTG tubes

MeSH Terms

Conditions

COVID-19; Virus Diseases

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Jörg Goldhahn, MD

  ETH Zurich

  STUDY CHAIR

• Susanne Ulbrich, Prof. Dr.

  ETH Zurich

  STUDY DIRECTOR

• Markus Stoffel, Prof. Dr.

  ETH Zurich

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Deputy director of the Institute for Translational Medicine

Study Record Dates

• First Submitted: May 5, 2020
• First Posted: May 6, 2020
• Study Start: April 27, 2020
• Primary Completion: February 4, 2022
• Study Completion: February 4, 2022
• Last Updated: February 23, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)